Metabolic syndrome affects the long‐term survival of patients with non‐endometrioid carcinoma of the uterine corpus

Objective To probe the influence of metabolic syndrome (MS) on the long‐term survival of patients with non‐endometrioid adenocarcinoma. Methods Between January 2003 and December 2012, 139 Chinese patients with non‐endometrial adenocarcinoma were analyzed in a retrospective study. Patients who had received any treatment before surgery were excluded. Survival times were compared between patients with and without MS. Results Overall, 41 (29.5%) patients had MS; the highest incidence of MS was observed in those with uterine serous carcinoma (19/45, 42.2%). For uterine serous carcinoma or adenosquamous carcinoma, MS was an independent predictive factor of morbidity (P=0.023 and 0.016, respectively). For the overall population, those with MS had a significantly lower survival rate than those without MS (P=0.008), and the median overall survival (mOS) was 15 months versus 55 months (P